Quarterly ResultAug 4, 2026, 04:08 PM
LeMaitre Vascular Q2 Sales $70.4M, EPS $0.74; Raises Dividend
AI Summary
LeMaitre Vascular, Inc. reported strong Q2 2026 results, with sales increasing 10% to $70.4 million and diluted EPS growing 23% to $0.74. The company's gross margin expanded to 72.1%, and operating income rose 26%. Artegraft sales were a significant driver, growing 34% and becoming the fastest-growing product. The Board also approved a quarterly dividend of $0.25 per share and provided positive full-year 2026 guidance, with sales expected to reach a midpoint of $276.3 million.
Key Highlights
- Q2 2026 Sales increased 10% (10% organic) to $70.4 million.
- Q2 2026 Diluted EPS grew 23% to $0.74.
- Gross margin improved by 210 bps to 72.1% in Q2 2026.
- Operating income rose 26% to $20.4 million, with an operating margin of 29%.
- Cash and short-term marketable securities increased to $376.2 million.
- Artegraft sales surged 34% in Q2, now accounting for 21% of total sales.
- Board declared a quarterly dividend of $0.25 per share, payable September 3, 2026.
- Full-year 2026 sales guidance midpoint is $276.3 million (+11% organic).
Price Impact
More from LMAT